BBBicara Therapeutics Inc.
10.79USDR
+0.56+5.47%
Last update at 22:37 GMT
USD
No tradesPost-market
Price target
32.60RUSD+21.81+202.13%
The 5 analysts offering 1 year price forecasts for Bicara Therapeutics Inc. have a max estimate of 48.00 and a min estimate of 8.00.
Analyst rating
Based on 7 analysts giving stock ratings to Bicara Therapeutics Inc. in the past 3 months.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong buy
6
Buy
0
Hold
1
Sell
0
Strong sell
0
EPS
Forecast
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
Q3 '25
Q4 '25
Q1 '26
−1.60
−1.20
−0.80
−0.40
0.00
Reported
Estimate
Currency: USD
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
Q3 '25
Q4 '25
Q1 '26
Reported
−0.45
−1.60
−0.39
−0.68
—
—
—
—
Estimate
—
−0.41
−0.33
−0.41
−0.55
−0.58
−0.58
−0.60
Surprise
—
−290.24%
−18.47%
−63.86%
—
—
—
—
Revenue
Forecast
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
Q3 '25
Q4 '25
Q1 '26
0.00
Reported
Estimate
Currency: USD
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
Q3 '25
Q4 '25
Q1 '26
Reported
0.00
0.00
0.00
0.00
—
—
—
—
Estimate
—
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Surprise
—
—
—
—
—
—
—
—
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.
Frequently Asked Questions
BCAX EPS for the last quarter is −0.68 USD despite the estimation of −0.42 USD. In the next quarter EPS is expected to reach −0.55 USD. Track more of Bicara Therapeutics Inc. financials and stay on top of what is up with the company.
In the next quarter Bicara Therapeutics Inc. revenue is expected to reach 0.00 USD. Check out Bicara Therapeutics Inc. revenue and earnings and make informed decisions.
According to analysts, BCAX price target is 32.60 USD with a max estimate of 48.00 USD and a min estimate of 8.00 USD. Check if this forecast comes true in a year, meanwhile watch Bicara Therapeutics Inc. stock price chart and keep track of the current situation with BCAX news and stock market news.
We've gathered opinions of 7 analysts rating BCAX stock in the past 3 months. Most of them backed up the strong buy trend, and after taking into account other opinions, the overall rating was calculated as strong buy. Note that it's not a trading advice — your own analysis is still required.